Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 27, 2009, Pages 11394-11399

  Schluep, Thomas ^a   Hwang, Jungyeon ^a   Hildebrandt, Isabel J ^b   Czernin, Johannes ^b   Choi, Chung Hang J ^c   Alabi, Christopher A ^c   Mack, Brendan C ^c   Davis, Mark E ^c  

^a Calando Pharmaceuticals   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c California Institute of Technology   (United States)

Author keywords

Camptothecin; Cancer; Cyclodextrin; Intracellular delivery; Polymer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIS ACETIC ACID CU 64; CAMPTOTHECIN DERIVATIVE; COPPER 64; IT 101; NANOPARTICLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CIRCULATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PENETRATION; DRUG RETENTION; DRUG SCREENING; HALF LIFE TIME; IN VIVO STUDY; KIDNEY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR; TUMOR CELL;

ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; COPPER; CYCLODEXTRINS; FLUORESCENT ANTIBODY TECHNIQUE; KIDNEY; MICE; MICE, SCID; MODELS, BIOLOGICAL; NANOPARTICLES; NEOPLASMS; POLYMERS; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

MUS;

EID: 67650500592     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0905487106     Document Type: Article

References (33)

1. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
2. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
3. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169.
4. Reddy JA, et al. (2007) Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67:4434-4442.
5. Tong R, Cheng J (2007) Anticancer Polymeric Nanomedicines. Polymer Reviews 47:345-381.
6. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782.
7. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46:6387-6392.
8. Tabata Y, Murakami Y, Ikada Y (1998) Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J Control Release 50:123-133.
9. Hobbs SK, et al. (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612.
10. Yuan F, et al. (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756.
11. Dreher MR, et al. (2006) Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98:335-344.
12. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9:1909-1915.
13. Tabata Y, Kawai T, Murakami Y, Ikada Y (1997) Electric charge influence of dextran derivatives on their tumor accumulation after intravenous injection. Drug Delivery 4:213-221.
14. Kirpotin DB, et al. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732-6740.
15. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104:15549-15554.
16. Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov 3:1023-1035.
17. Heidel JD (2006) Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opin Drug Deliv 3:641-646.
18. Cheng J, Khin KT, Davis ME (2004) Antitumor activity of beta-cyclodextrin polymer-campthothecin conjugates. Mol Pharm 1:183-193.
19. Schluep T, Cheng J, Khin KT, Davis ME (2006) Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 57:654-662.
20. Schluep T, et al. (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 12:1606-1614.
21. Numbenjapon T, et al. (2009) Preclincal results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res, in press.
22. Schluep T, et al. (2009) Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 15:181-189.
23. Oliver JC, Yen Y, Synold T, Schluep T, Davis ME (2008) A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors. J Clin Oncol 26:14538 (abstr).
24. Riches AC, Sharp JG, Thomas DB, Smith SV (1973) Blood volume determination in the mouse. J Physiol 228:279-284.
25. O'Connor SW, Bale WF (1984) Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. Cancer Res 44:3719-3723.
26. Tirona RG, Schwab AJ, Geng W, Pang KS (1998) Hepatic clearance models: Comparison of the dispersion and Goresky models in outflow profiles from multiple indicator dilution rat liver studies. Drug Metab Dispos 26:465-475.
27. Jorgensen KE, Moller JV (1979) Use of flexible polymers as probes of glomerular pore size. Am J Physiol 236:F103-F111.
28. Braet F, Wisse E (2002) Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: A review. Comp Hepatol 1:1.
29. Alley SC, et al. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconj Chem 19:759-765.
30. Hashizume H, et al. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380.
31. Moore A, Marecos E, Bogdanov A, Jr, Weissleder R (2000) Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214:568-574.
32. Cheng J, Khin KT, Jensen GS, Liu A, Davis ME (2003) Synthesis of linear, betacyclodextrin-based polymers and their camptothecin conjugates. Bioconj Chem 14:1007-1017.
33. Loening AM, Gambhir SS (2003) AMIDE:A free software tool for multimodality medical image analysis. Mol Imaging 2:131-137.